Eicosanoids and exosomes : a link between macrophages and lung cancer by Lukic, Ana
From MEDICAL BIOCHEMISTRY AND BIOPHYSICS 
DEPARTMENT 
Karolinska Institutet, Stockholm, Sweden 
EICOSANOIDS AND EXOSOMES: A 
LINK BETWEEN MACROPHAGES AND 
LUNG CANCER 
Ana Lukic 
 
Stockholm 2017 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print AB 2017 
© Ana Lukic, 2017 
ISBN 978-91-7676-849-5 
  
Eicosanoids and exosomes: a link between 
macrophages and lung cancer 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
 
Public defense at Karolinska Institutet, Samuelssonssalen, Tomtebodavägen 6, Solna. 
Thursday November 23
rd
 2017, at 13:00. 
 
 
By 
 
Ana Lukic 
 
 
Principal Supervisor: 
Prof. Olof Rådmark 
Karolinska Institutet 
Department of Medical Biochemistry and 
Biophysics 
Division of Chemistry II 
 
Co-supervisor(s): 
Prof. Susanne Gabrielsson 
Karolinska Institute 
Department of Medicine 
Immunology and Allergy Unit 
 
Prof. Bengt Samuelsson 
Karolinska Institutet 
Department of Medical Biochemistry and 
Biophysics 
Division of Chemistry II 
 
 
Opponent: 
Prof. Anita Sjölander 
Lund University 
Department of Translational Medicine 
 
Examination Board: 
Prof. Jonas Fuxe 
Karolinska Institute 
Department of Microbiology, Tumor and Cell 
Biology 
 
Prof. Mikael Adner 
Karolinska Institute 
Department of Environmental Medicine 
 
Prof. Esbjörn Telemo 
University of Gothenburg 
Department of Rheumatology and Inflammation 
Research 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        A Marco 
  
  
  
ABSTRACT 
Chronic inflammation increases the risk of lung cancer. Macrophages (MO) are important 
players in inflammation, with regulatory and executive functions. Eicosanoids and exosomes 
can be both triggers and mediators of these functions. Cysteinyl leukotrienes (CysLTs) are 
the most potent mediators of broncho-constriction in the lungs, a function exerted via 
CysLT1 receptor. Their function in asthma is well described, but little is known about 
CysLTs and lung cancer.  
In the first study we investigated how the interaction between pulmonary epithelium and 
leukocytes affects CysLTs formation. Monocytic cells and eosinophils formed LTC4, which 
was exported and promptly converted to LTD4 by pulmonary epithelial cells in a transcellular 
manner. The lung cancer cell line A549 expressing γ-glutamyl transpeptidase 1 (GGT-1) 
showed a high activity. Exosomes released by A549 cells also contained GGT-1 and 
efficiently converted LTC4 to LTD4. On the other hand, healthy bronchial epithelial cells 
(PBEC) expressing GGT-5 formed LTD4 12 times more slowly. The results highlight an 
active role for epithelial cells and their exosomes in biosynthesis of LTD4, which may be of 
particular relevance in the lung, given that LTD4 is the most potent agonist of CysLT1.  
MOs can be differentiated from blood monocytes with GM-CSF and M-CSF, resulting in 
cells primed toward the inflammatory M1- and resolving M2-states. A comprehensive 
analysis of eicosanoid formation in these two in vitro models is missing and our second study 
focused on this gap. By LC-MS analysis, we observed that both MO phenotypes released 
pro-resolving lipid mediators (PGE metabolite, LXA4) in resting conditions. When the same 
cells were incubated (30 min) with bacterial stimuli, there was a shift to pro-inflammatory 
eicosanoids: M-CSF MOs produced high amounts of LTC4, relevant for M2 functions in 
asthma. GM-CSF cells expressed the highest levels of cPLA2, 5-LO and FLAP; and in 
ionophore incubations these cells also produced the highest levels of 5-HETE. However, M-
CSF MO formed more products apparently due to a better response to bacterial stimuli, 
demonstrated by enhanced mobilization and activation of cPLA2 and 5-LO. In conclusion, 
GM-CSF and M-CSF can regulate specific pathways in MOs, and it appears that eicosanoid 
biosynthesis primarily reflect the cellular response and activation mechanisms, rather than the 
protein expression profile.  
In colon cancer a pro-tumorigenic effect of LTD4 but not LTC4 has been demonstrated. A 
pro-tumorigenic effect has been shown also for exosomes. To extend the findings of our first 
study, we used pleura exudates from lung cancer patients to isolate primary cancer cells and 
exosomes. Both cells and exosomes metabolized LTC4 to LTD4, and we also found that 
exosomes stimulated CysLTs formation in the cancer cells. Cancer cells from all patients 
expressed CysLT1, and exosomes promoted their migration and survival in a CysLT1 
dependent manner, as demonstrated by the inhibition by montelukast (MK) treatment, a 
CysLT1 antagonist used to treat asthma. 
In cancer, interactions between the transformed cancer cells and other recruited cell types in 
the tumor are important. Tumor associated macrophages (TAMs) provide cancer cells with a 
suitable low-grade inflammation milieu including growth promoting factors. Taken together, 
the results in this thesis suggest a novel pro-tumorigenic mechanism based on this theme, 
driven by the exosomes/CysLT1 cascade: TAMs provide LTC4 that lung cancer cells and 
their exosomes convert to LTD4. Via CysLT1 receptor this promotes survival and migration 
of the cancer cells. A protective effect in lung cancer has been previously described for MK 
and our results suggest a possible mechanism for this, driven by the exosomes/ CysLT1 
cascade, further encouraging the use of this drug in lung cancer treatment. 
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INTRODUCTION 
A pinch of evolution  
In 1859, Darwin published On the Origin of Species. He postulated that all existing life forms 
originate from the same ancestor and that species evolve by natural selection. Although 
science and technology allow humans to challenge the action of evolution, our ‘starting pack’ 
is the result of millions of years of selection and whenever our physiological condition is 
perturbed, a cascade of defensive mechanisms is activated to restore homeostasis. Noxious 
stimuli will trigger inflammation, a refined arm of both innate and adaptive immunity that 
involves vascular leakage followed by leukocyte recruitment and activation at the site of 
damage, and finally “reconstructive” tissue healing. The mechanisms behind all these effects 
differ depending on the tissue, the type of trigger, and the effector cells [1, 2].  
Evolution shapes life in term of cost and benefits. Although inflammation may compromise 
the physiological function of tissue, the benefit of clearing the harmful stimuli is superior. 
This biological response is affected by  surrounding environmental factors: in the past century 
the development of antibiotics, and extensive changes in diet, stress and exercise have put a 
new selective force on our immune system, without providing time for evolution to readjust 
the inflammatory mechanisms. The inflammatory response can easily be dysregulated and 
loose its transitory properties in favor of a chronic condition [3]. Chronic inflammation is 
well connected with several diseases, including cancer, diabetes, obesity and cardiovascular 
diseases, which are the ‘plague’ of modern age. According to the last update by the World 
Health Organization (WHO), the second leading cause of death in 2015 across the world was 
lung related pathologies: cancer and inflammatory diseases, such as Chronic Obstructive 
Pulmonary Disease (COPD), and respiratory infection. The respiratory system is in fact 
particularly susceptible to inflammation, also in light of its ‘open’ anatomy: lungs are 
constantly exposed to viruses, bacteria, allergens, and the particles and smoke in air pollution. 
The pulmonary epithelium, assisted by resident leukocytes such as macrophages, represents 
the checkpoint where these external antigens may or may not be recognized as harmful and 
thus trigger the immune response [4]. An efficient immune response will fulfil the 
pathophysiological role in lung defense, clear the harmful stimuli, and restore the physiology 
of the tissue. To accomplish this task cells must communicate and eicosanoids and exosomes 
represent two fundamental categories of messengers in the lung.  
In the following  studies, we investigated eicosanoid biosynthesis (in particular one step in 
formation of leukotriene D4) in connection to exosomes, to further understand how 
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macrophages and lung cancer cells may contribute to inflammatory conditions in the lung 
microenvironment.  
 
Chapter 1. Arachidonic acid derived eicosanoids 
Eicosanoids are lipid mediators mostly derived from arachidonic acid (AA) that exert a 
pivotal role in inflammation. They have several biological effects, both in homeostasis and in 
pathological conditions, in the inflammatory phase as well as in the resolution of 
inflammation [5]. AA is the common name of 5, 8, 1, 14-cis-eicosatetraenoic acid, an ω-6 
polyunsaturated fatty acid (PUFA) found in algae, plants and animals. AA can be 
metabolized via lipoxygenases (LO), cyclooxygenases (COX) and cytochrome P450 (CYP) .  
Detection of AA and the eicosanoid forming enzymes across the life domains indicate that 
the derived signaling molecules exert positive functions on survival that have been preserved 
over millions of years by natural selection [6, 7]. The CYP pathway is most likely the oldest, 
given that this superfamily of proteins is extensively present across all  domains of life [8]. 
The exact functions of AA-derived mediators and eicosanoid-like molecules in primordial 
organisms are yet to be described, but in plants and animals more is known. Interestingly, 
eicosanoids show mainly regulatory functions in plants: peaks in LO activities are detected 
during growth, while  prostaglandin-like molecules  participate in flowering [9, 10].  
In animals, important functions of eicosanoids are exerted during the immune response. Both 
plants and animals possess an innate immune system, but inflammation is observed only in 
the animal kingdom, and eicosanoids seem evolutionary optimized in regulating the different 
phases of the inflammatory process. For example, leukotrienes (LTs) are the most studied LO 
products and their functional cascade, including enzymes and receptors, are found only in 
vertebrates [6]. 15-LO is an enzyme involved in formation of lipid mediators that can resolve 
inflammation. Recently it was demonstrated that the most evolved primates, including 
humans and chimpanzees, possess a 15-LO with higher capacity for the biosynthesis of 
resolving lipid mediators, in comparison to the 15-LO of other animals, including mice, rats 
and pigs [11]. The selection for an enhanced ability to form lipoxins in primates may have 
furnished an evolutionary advantage in resolving inflammation more efficiently, thus 
supporting a more balanced immune response and better survival. Moreover, it was proposed 
that development of a refined brain may compete with the development of the innate immune 
system [12], and the capacity to resolve inflammation more quickly may have been one of the 
factors promoting brain development in primates.    
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Different types of stimuli, such as pathogens, antigens, and cytokines, can lead to activation 
of phospholipase A2 enzymes (PLA2). PLA2 is a superfamily of proteins and the most studied 
members are secreted PLA2 (sPLA2) and cytosolic PLA2 (cPLA2), both involved in AA-
release, and calcium independent PLA2 (iPLA2). cPLA2 is the main enzyme to hydrolyze AA 
from the membrane. When activated by Ca
2+
 binding and phosphorylation, cPLA2 migrates 
to the nuclear membrane and releases AA from phospholipids [13]. Once AA is free, it 
undergoes one of the three metabolic routes – LO, COX, CYP- depending on the proximity, 
expression and activation state of each enzymatic route (Figure 1) [5].  
 
 
Figure 1. Summary of the AA-metabolism. 
 
Chapter 1.1.1 5-LO pathway: the inflammatory side 
AA may become substrate to 5-lipoxygenase (5-LO). Similarly to cPLA2, 5-LO activity is 
tightly regulated. Ca
2+
 signaling and ATP activate 5-LO by direct binding. Phosphorylation at 
serine-271 and serine-663 results in increased 5-LO activity, while the opposite effect is 
obtained when phosphorylation occurs at serine-523. Subcellular localization can also affect 
5-LO activity: proximity to cPLA2 and cell membranes results in higher activity [14]. The 
activation and the translocation of 5-LO  is supported by two scaffold proteins, 5-LO 
activating protein (FLAP) and coactosin-like protein (CLP) [15]. Once activated, 5-LO 
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catalyzes the two steps necessary to convert AA to LTA4, an unstable epoxide. LTA4, can be 
metabolized by the cytosolic LTA4 hydrolase to LTB4 or it can be conjugated to glutathione 
(GSH) by nuclear membrane-associated LTC4 synthase to form LTC4. LTC4 may be further 
converted to LTD4 and LTE4 by sequential peptide cleavages of the GSH moiety (Figure 2). 
 
 
Figure 2. Overview of the leukotriene biosynthesis. 
 
LTs are potent pro-inflammatory mediators which bind to receptors; LTB4 exerts its role via 
BLT1/2, while CysLTs bind CysLT1/2 [16].In the last decade novel receptors for LTE4 have 
been described, such as P2Y12 and GPR99 [17, 18]. Depending on the receptor expression 
and distribution on different cell types, LTs mediate different effects in the inflammatory 
response. They are potent chemotactic agents; they increase cellular adhesion and motility, 
facilitating the recruitment and accumulation of leukocytes in the inflammatory 
microenvironment. LTB4 is one of the most potent chemoattractants to neutrophils, while 
LTD4 recruits dendritic cells and eosinophils. Both LTB4 and LTD4 can promote migration ot 
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Th17 cells [19] and LTB4 also promotes the recruitment of activated regulatory T cells 
(Tregs) in lungs after acute injury [20]. LTB4 contributes to host defense also by enhancing 
phagocytosis. CysLTs are fundamental players in respiratory inflammation: they regulate 
bronchoconstriction, vascular permeability, mucus secretion and airway remodeling [21, 22].  
LTD4, the first metabolite of LTC4, is one of the most potent broncho-constricting molecules 
in humans, at least 1000 times more potent than histamine; it exerts a rapid effect, and in 
comparison to histamine it induces a prolonged bronchoconstriction [23]. LTD4 has 10- to 
100-fold higher affinity to CysLT1, the most expressed CysLT receptor in lung tissue [24] 
and this makes LTD4 one of the most important mediators in lung inflammation. However, 
both LTC4 and LTD4 induce a similar broncho-constructive response [25], which probably 
results from the further metabolism of LTC4 to LTD4. Finally, dipeptidase enzymes catalyze 
metabolism of LTD4 to the weakest CysLT1 agonist LTE4 [26].  Two different strategies can 
prevent the action of LTs: inhibition of the biosynthetic enzymes or receptor antagonists. 
Today several drugs targeting the LTs pathway are commercially available, such as zileuton, 
a 5-LO inhibitor, or montelukast (MK) and zafirolukast, CysLT1 antagonists. The use of Cys-
LT1 antagonists in treatment of asthma and allergic rhinitis is well established. Moreover, the 
discovery in the last two decades of the 5-LO role in other diseases than allergy, such as 
atherosclerosis and cancer, is driving the research toward new pharmacological applications 
[27]. 
Another possible way to target LTD4 action is by acting on γ-glutamyl transpeptidase (GGT, 
formerly called γ-glutamyl transferase), the enzyme that converts LTC4 to LTD4. This 
enzyme is located on the extracellular side of the plasma membrane, mostly on epithelial cells 
[28] and it is fundamental in the metabolism of GSH, where it catalyzes the hydrolysis and 
transfer of γ-glutamyl moieties [29]. LTC4, which is formed by conjugation of LTA4 with a 
GSH molecule, can be further metabolized by GGT, by cleavage of the γ-glutamyl, to 
produce LTD4. The GGT family includes different proteins, but the functional roles are 
known only for few of these. GGT-1 and GGT-5 are the two family members known to 
convert LTC4 to LTD4. Data from mouse and human models are different in regard of LTD4 
biosynthesis: in mice 90% of LTD4 is formed by GGT-5, while in humans both GGT-1 and 
GGT-5 metabolize LTC4, although GGT-1 is much faster [30]. GGT-1 is used as a diagnostic 
marker in several diseases characterized by high GSH levels, including cancer, but research 
failed to develop effective drugs to target this enzyme. GGT inhibitors tested in clinical trials 
include glutamine analogues, which proved to be toxic at concentrations required to inhibit 
the enzymatic activity. Only in recent years novel noncompetitive and non-cytotoxic 
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inhibitors have been developed, reviving once again the research for GGT-1 targeting drugs 
to test in clinical trials [31].  
 
Chapter 1.1.2 5-LO pathway: anti-inflammatory and resolving products  
The 5-LO metabolites derived from AA do not only have  potent pro-inflammatory 
properties. This enzyme is involved in the biosynthesis of other molecules fundamental in the 
resolution phase of the immune response. LTA4, the unstable epoxide, can be transported 
outside of the cells and further metabolized in a transcellular manner. Neutrophils release 
LTA4, donating this substrate to cells that do not possess 5-LO, such as platelets [32]. These 
cells possess LTC4s and can produce LTC4. They also possess 12-lipoxygenase, which can 
catalyze the conversion to lipoxin A4 and lipoxin B4 (LXs). These lipid mediators can be 
formed by the same enzymes with a reversed order: epithelium/endothelium possessing 15-
LO can produce and export 15(S)-HpETE, which in presence of leukocytes may be converted 
via 5-LO to LXA4/LXB4  [33]. The biological action of LXs covers a range of effects in the 
resolution of lung inflammation: they reduce bronchoconstriction; they stimulate the 
phagocytosis of apoptotic PMN by macrophages; they block eosinophil trafficking by 
inhibition of eotaxin secretion [34]. The receptors that mediate these effects are still 
investigated; LXA4 binds to ALX/FPR2, mediating the reduction of pro-inflammatory 
cytokine release and clearance of apoptotic PMN, but a LXB4 receptor has not yet been 
clearly identified [22]. The lack of the complete description of the LXs signaling cascade did 
not stop the development of LXs analogs, currently investigated as potential drugs to 
stimulate resolution in inflammatory diseases.  
 
Chapter 1.2 COX pathway  
After the release from the nuclear membrane phospholipids, AA can be metabolized by 
COX-1 and COX-2, generating PGH2, which is further metabolized by tissue-specific 
enzymes to generate the large family of prostanoids, which includes prostaglandins and 
thromboxane (Figure 1). COX-1 and COX-2 are homodimeric hemeproteins, bound to the 
nuclear membrane and to the adjacent endoplasmic reticulum. COX activity is not regulated, 
and when AA is available PGs are produced. Thus, in many cell types the regulation of 
cPLA2 activity is important for regulation of PG biosynthesis. As for the LTs, the effects of 
prostanoids are mediated by G-protein coupled 7-TM receptors [35]. Prostanoid biosynthesis 
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is increased in inflammation, but the exact role exerted by these messengers is cell specific, in 
part due to the variance in the expression of the receptors. For instance, PGE2, one of the 
most potent and studied inflammatory mediators, is involved in the regulation of four of the 
five signs of inflammation: rubor, tumor (swelling/edema), inflammatory pain, and fever. 
Yet, depending on the stage of the immune response, PGE2 can act as an anti-inflammatory 
and immunosuppressive agent, for example by increasing infiltration and activity of Treg 
cells and MDSC cells [36]. PGE2 can also stimulate production of LXs, in the so called 
“eicosanoid class-switching” [37]. The complementary ability to induce or reduce 
inflammation is explained by the presence of 4 receptors, expressed heterogeneously in 
human tissue, and characterized by different affinity to PGE2, high for EP3 and EP4, low for 
EP1 and EP2 [36]. In lungs PGE2 has a unique protective role, mediated by EP4, the most 
expressed PGE2 receptor in this tissue. EP4 mediates the bronchodilator effect of PGE2, the 
inhibition of eosinophil and neutrophil trafficking, as well as the decrease in cytokines 
production by human alveolar macrophages [38]. Other notable COX-products include PGD2 
and Thromboxane (TX) A2, which most important functions are linked to airway 
inflammation and platelet activation, respectively [39, 40]. Inflammatory conditions can be 
treated with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as aspirin, ibuprofen and 
paracetamol. These drugs exert their action also by inhibiting COX activity and PGs 
biosynthesis. [41]. Because PGs can exert both inflammatory and anti-inflammatory 
properties, treatment with NSAIDs may cause negative side effects. An example: aspirin 
inhibits COX-derived PGE2, which in turn can inhibit CysLTs biosynthesis in lung, as part of 
the anti-inflammatory and broncho-protective process [42]. A recent study showed that PGE2 
acts through EP2 to inhibit CysLTs biosynthesis by mast cells, resulting in less potent 
bronchoconstriction after challenge [43]. Thus, disruptions of PGE2 production cause a 
significant percentage of patients with lung inflammatory disease to develop aspirin-
exacerbated respiratory disease (AERD), characterized by severe eosinophilic inflammation 
driven by CysLTs, whose negative regulation is impaired by the lack of PGE2 [44].  
 
Chapter 1.3 CYP pathway 
This  is the third metabolic pathway that free AA can enter; it includes 57 known proteins and 
almost half of these enzymes can utilize AA as substrate [45]. In fact, several members can 
oxygenate AA on C16-C20 resulting in mono-HETEs. One of these is 20-HETE, a potent 
vascular modulator that execute some of its functions via EGFR [46] and that can modulate 
miR-133 and miR-143, known to affect the phenotype of smooth muscles cells [47]. The 
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unique mediators formed via this pathway are epoxyeicosatrienoic acids (EETs) and three 
major human CYP are involved in this metabolism: CYP2J2, CYP2C8 and CYP2C9; 
notably, the last CYP is the most expressed in the lungs [48]. The function of EETs is mainly 
studied in cardiovascular diseases, due to their ability to induce vasodilatation and thus act as 
protective agents [49]. Although EETs appear to have anti-inflammatory properties, they also 
have angiogenic and apparently pro-tumorigenic effects:  in mouse models of different types 
of cancer it was observed that the endothelial derived EETs play a crucial role in promoting 
tumor growth and metastasis [50]. An important mechanism to regulate EET functions is 
further metabolism by the soluble epoxide hydrolase (sEH), which results in the less potent 
dihydroxyeicosatrienoic acids (DHETs). As a consequence, targeting sEH may be a potential 
therapy where EETs function is crucial to pathogenesis. Last, but not least, CYP enzymes 
also contribute to PGs formation: PTGIS and TXAS, two of the downstream enzymes of the 
PGH2 metabolism, belong to the CYP family and form PGI2 and TXA2 respectively. 
 
Chapter 1.4 Eicosanoids in pulmonary disease  
As described, AA metabolites are fundamental mediators of the immune response, with both 
pro- and anti-inflammatory actions. Several steps of the AA cascade are tightly regulated. 
Dysregulation of this metabolic network may lead to prolonged inflammation with aberrant 
tissue remodeling, a common feature of many lung associated diseases, such as asthma, 
COPD, and lung cancer [51, 52]. For example, asthma patients can have high levels of 
CysLT in body fluids, such as blood, BAL, urine, and sputum [53]. High levels of CysLTs in 
pulmonary tissue can lead to airway obstruction, due to increased broncho-constriction, 
mucus production, and vascular permeability. CysLTs also promote lung inflammation by 
enhancing the migration of eosinophils  in synergy with IL-33 [54] and later their trafficking 
toward lymph nodes [55]. Although higher LTB4 levels have been reported as well, the role 
of LTB4 in asthma is unclear: treatment with BLT1 antagonists did not inhibit the asthmatic 
response to allergen challenge in patients with allergic asthma [56], but these results do not 
exclude a primary role in non-allergic asthma. Alveolar macrophages isolated from broncho 
alveolar lavage (BAL) of patients with sarcoidosis release more LTB4 compared to cells from 
healthy donors [57]. COX-derived metabolites display heterogeneous effects. Mast cell-
derived PGD2 triggers the asthmatic response [58], while PGE2 exerts a protective effect, the 
disruption of which may lead to AERD. Patients with COPD have high levels of LTB4 and 
PGE2 in exhaled breath condensate (EBC) compared to healthy subjects [59]. A possible 
explanation for high PGE2 in COPD may be its anti-inflammatory properties in the lung [38, 
  11 
60]. TXA2 is also significantly increased in urine of patients with COPD: increased 
production of TXA2 may contribute to  vascular complications such as pulmonary 
hypertension [61].  
Dysregulation of the eicosanoid cascade has also been linked to cancer. Increased production 
of LTs and PGs has been observed for malignant tumors. PGE2 and in some case also LTB4 
contribute to a favorable milieu for cancer cells, promoting their proliferation, migration, 
invasiveness, induction of angiogenesis and suppression of the immune response  [62]. 
Inhibition of 5-LO can reduce lung tumorigenesis in mice [63] and proliferation in human 
lung cancer cell lines [64]. Interference with LTB4 signaling also results in better survival, as 
demonstrated in a BLT1-/- knock out mouse model of lung cancer [65]. Evidence on the 
function of LTB4 in tumorigenesis abounds in comparison to CysLTs, far less investigated. 
So far, two publications have presented different results on LTC4 function in lung cancer. In a 
Lewis lung cancer mouse model, knock out of LTC4s did not affect primary tumor growth 
nor liver metastasis [66]. In the same study, depletion of 5-LO resulted in enhanced tumor 
growth caused by reduced cytotoxic CD8+ T cell recruitment [66]. This should reflect a 
function of LTs to stimulate the immune system to attack and kill cancer cells. However, in 
another  study, 5-LO knock out reduced lung metastasis in a mouse model with breast cancer, 
in a LTC4/CysLT2 and LTB4/BLT2 manner [67]. This may reflect different functions of LTs 
in tumor progression, depending on the stage. For example, it is possible that LTs promote a 
low-grade inflammation tumor microenvironment, stimulating e.g. metastasis formation. 
Epidemiological studies support the hypotheses that CysLTs may contribute to lung cancer: 
recently, a Taiwanese 20 year retrospective study showed that asthma patients treated with 
MK have lower risk to develop lung cancer [68], suggesting that CysLT receptor antagonists 
may be beneficial to lung cancer patients. The same group showed that MK indeed induces 
apoptosis in A549 cells, a commonly investigated human lung cancer cell line, and reduces 
tumor growth in a lung cancer mouse model [69]. However, early clinical trials showed that 
patients with advanced non-small-cell lung cancer (NSCLC) did not respond to zileuton 
treatment or LTB4 antagonists [70, 71]. Moreover, 5-LO expression did not correlate with 
prognosis, in contrast COX-2 expression did: in fact, patients with high COX-2 expression 
responded positively to celecoxib therapy [70]. A valid argument on why 5-LO inhibitors 
may fail as treatment against cancer depends on the nature of AA metabolism: blocking AA 
from entering 5-LO may shift this substrate toward COX, as observed in a co-culture model 
with lung epithelial cells and alveolar macrophages [72]. This will further enhance the 
production of PGs, as Poczobutt et al have observed in their lung cancer mouse model 
depleted of 5-LO [66]. PGE2 has several pro-tumorigenic effects, including inhibition of 
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cytotoxic T cells response, which results in an immunosuppressed tumor microenvironment 
(TME) [36]. Another important way for PGE2 to promote tumorigenesis is via Tregs: these 
cells are fundamental to maintain immunosuppression, and lung cancer cells can directly 
modulate Treg via COX-2/PGE2 cascade [73]. In agreement with this, recently it was 
observed that urinary PGE2 correlates positively with intratumor infiltration of Tregs in 
patients with lung cancer [74]. Moreover, PGE2 action is not limited to the modulation of 
TME alone: A549 cells secrete this prostaglandin to self-promote proliferation in a EGFR 
dependent mechanism [75]. Furthermore, xenograft tumors derived from mPGES1-depleted 
A549 cells, display a slower growth and tumor progression, compared to WT cells [76]. The 
fact that both LO and COX pathways synthesize pro-tumorigenic metabolites is the driving 
force behind the development of dual 5-LO and COX inhibitors in the last years [77].  
Last, CYP products have also been studied in relation to cancer. EETs have positive effect on 
cancer migration and invasion, as observed in both mammary cancer cell line and lung cancer 
cell line, including A549 cells; similarly, overexpression of CYP2J2 promotes both tumor 
growth and lung cancer formation in a mouse model [78]. In a more recent study, it was 
reported that tumor growth and number of metastasis in the lungs is increased in sEH-
depleted mice, further supporting a pro-tumorigenic effect for EETs [50]. One of the 
mechanisms behind EETs pro-tumorigenic effects relies on neutrophil recruitment; in fact 
ablation of these cells blocks the pro-metastatic effect of 14,15-EET treatment [79].  
 
Chapter 2.  Other substrates for the LO-COX-CYP cascades 
Archaeological and evolutionary studies showed that pathologies characterized by chronic 
inflammation were not that common 10.000 years ago as today; one of the major contributors 
to these differences seems to be the change in our diet: the ω-6/ω-3 fatty acids ratio in the 
past was 1 while the typical modern western diet has a ratio of 15/1 [80]. Today it is generally 
believed that a diet enriched in ω-3 fatty acids results in a more balanced inflammatory 
response , and possibly better resolution of inflammatory conditions [81, 82]. The ω-6 family 
includes AA and linoleic acid (LA), a PUFA with 18-carbon chain length. In the ω-3 group, 
docosahexaenoic acid (DHA) and epoxydocosapentaenoic acid (EPA) are the most studied 
members, with 22-carbon long and 20-carbon long chains respectively. In the past decades, 
science has unveiled fundamental anti-inflammatory and pro-resolving function of DHA and 
EPA derived mediators, which strengthens the hypothesis that an ω-3 enriched diet is  
beneficial. One of the most exiting aspects of the eicosanoid metabolism is that many of the 
  13 
enzymes metabolizing AA are active with other PUFA substrates, including LA, DHA and 
EPA (Figure 3). 
 
 
 
 
 
 
 
 
Figure 3. Other PUFAs metabolism via LO-COX-CYP pathways. 
 
LA is the second most abundant PUFA (after AA) in PBMC [83] and it's metabolite 13-
HODE, formed via 15-LO, contributes to bronchial injury in asthmatic patients [84]. The 
pathogenesis of COPD also correlates with LA metabolites: a recent lipidomic study on 
BALF from female, but not male, patients showed increased concentration of the CYP 
derived LA metabolites EpOMEs and DiHOMEs, suggesting a gender specific lipid mediator 
signature [85]. In cancer research, LA metabolites have shown contrasting results, with some 
models supporting an anticancer effect, while others demonstrate a pro-tumorigenic one [86]. 
EDPs are class of active lipid mediators derived from DHA, via CYP: they can counteract 
VEGF effect on HUVEC and inhibit metastasis in a Lewis lung metastasis model [87].  
The most studied DHA and EPA metabolites have potent resolving functions: they have anti-
inflammatory properties and promote resolution of inflammation, and return to homeostasis 
[37]. Specialized pro-resolving mediators (SPM) include EPA-derived E-series resolvins 
(RvE), and DHA-derived D-series resolvins (RvD), protectins (PD) and maresins: all are 
formed via several enzymatic steps including, in different order, 5-LO, 12/15-LO, CYP and 
COX-2 [88]. The LXs was the first subgroup of SPM to be described and their functions are 
the best characterized so far [89]. Of interest, aspirin not only induces the formation of some 
of the LXs, but also of some resolvins: aspirin-triggered RvD1 promotes resolution of the 
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inflammatory response in a sterile pneumonia mouse model, by enhancing bacterial clearance 
by macrophage phagocytosis among other factors [90]. The RvD1 can also counteract EMT 
transition in A549 cells: EMT stands for epithelial-to-mesenchymal transition, a fundamental 
event in cancer dissemination and metastasis formation. [91]. The D and E series of resolvins 
often have congruent effects: for example, both RvE1 and RvD1 downregulated TNFα + IL-6 
induced overexpression of COX-2 and VEGF in human pulmonary arteries [92]. Protectin D1 
(PD1) inhibits replication of influenza virus in infected A549 cells [93]. In the same study, 
other known AA, DHA and EPA metabolites, including 15-HETE and 17-HDoHe (a 
precursor of D-resolvins), showed similar inhibiting properties. However, neither RvE1 nor 
RvD1 affected virus replication, suggesting that the inhibitory effect is not retained from 17-
HDoHe [93].  Maresins are the latest addition to the SPM family; they are DHA derived 
metabolites, formed via 12/15-LO and macrophages are a primary source [94]. Recently it 
was observed that macrophages exploit the LTC4s-GGT enzymatic cascade to further 
metabolize maresins, forming conjugated forms [95]. Stable analogs of SPM are currently 
under investigation as potential therapy to stimulate or reduce aberrant inflammatory 
responses [96]. 
 
Chapter 3. Exosomes 
Intercellular communication is a fundamental aspect of the immune system and it occurs in 
different ways. Many cells secrete small molecules that can target themselves in an autocrine 
loop, or other cells, in the neighborhood or in distant sites. Eicosanoids can target cells in the 
close proximity, in a paracrine fashion. Another channel of intercellular communication is by 
extra cellular vesicles, membrane vesicles defined primarily by size and origin. 
Microvesicles, sized 100-1000 nm, are shed from the plasma membrane while exosomes, 
sized 40-100 nm, are of endocytic origin [97].  In 1987 Johnstone et al described the vesicles 
released by reticulocytes during the maturation stage and called these exosomes. They 
concluded that other cell types present in blood did not release exosomes, and that the 
primary function of these vesicles was to remove unnecessary functional proteins during 
erythropoiesis [98]. After 30 years of research scientists proved that all cell types investigated 
so far produce exosomes, containing proteins and other classes of biomolecules. One of the 
most interesting properties of exosomes is their ability to transfer functional mRNA and 
miRNA between cells [99]. From an evolutionary point of view, exchange of genetic material 
in form of DNA and RNA represents a type of horizontal transfer, one of the oldest and most 
important ways to exchange genetic information prior to the development of sexual 
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reproduction [100]. After infection of cells, viruses can exploit the exosome machinery to 
spread viral miRNA [101]. Other pathogens, including parasites, fungi and bacteria, can 
exploit exosomes as a shuttle to disseminate infection [102]. This raises the question on how 
ancient and evolutionary selected the exosomal apparatus is. Except mammalian cells, plants 
also appear to form exosomes-like vesicles [103] but a clear evolutionary perspective has yet 
to be explored. The general nomenclature of extracellular vesicles is not clearly defined but it 
is generally recognized that exosomes share a specific set of molecules and a typical 
biogenesis [104].  
 
Chapter 3.1 Biogenesis  
Multivesicular bodies (MVBs) originate from the late endosome, a cellular compartment 
containing molecules from the plasma membrane, the cytosol and the Golgi. Here the protein 
sorting of the future exosomal cargo is performed by a multi-protein complex called 
Endosomal Complex Required for Transport (ESCRT). Exosomes are released when MVBs 
do not fuse with lysosomes for degradation, but with the plasma membrane, thus releasing the 
nano-vesicles formed by inward budding of the MVB membrane (Figure 4) [105]. 
 
 
Figure 4. Formation and release of exosomes. 
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 Exosomes constitute a heterogeneous population of vesicles and the ESCRT molecular 
machinery may be responsible for the genesis of many subtypes of exosomes. However, in 
recent years also ESCRT-independent exosome release has been demonstrated in different 
cell types [97].  The biogenesis of exosomes explains why these vesicles are enriched in 
endosomal markers such as tetraspanins (CD9, CD63, and CD81). Their content of cytosolic 
and plasma membrane proteins, lipids and RNA usually reflect the parent cells. However, the 
cargo is specifically selected and not just a sample of the cell content.  
 
Chapter 3.2 Function of exosomes 
Investigations of the exosomal load unveiled their role as mediators of intercellular 
communication: exosomes deliver mRNAs, which may be translated to functional proteins 
following the uptake by recipient cells. Also miRNAs are packed within the vesicles, and 
higher expression of distinct miRNA sequences can be detected in exosomes compared to 
parental cells [99]. Exosomes released by immune-competent cells may carry the parental 
cell function during the immune response [106]. For example, dendritic cell derived 
exosomes carry different surface molecules with a specific function, such as adhesion 
(CD54), co-stimulation (CD80, CD86) or antigen presentation (MHC-I/II). Dendritic cell 
exosomes can activate T cells, more efficiently when derived from mature dendritic cells 
compared to immature dendritic cells and also independently of MHC molecules [107, 108]. 
Dendritic cell exosomes can also act indirectly, via other mediators formed by B cells or 
other dendritic cells [109, 110]. Intriguing results have been published regarding exosomes 
and lung diseases. Admyre et al first reported that BAL fluid contains exosomes, enriched in 
co-stimulatory molecules such as MHC-I/II and CD54, similarly to dendritic cell derived 
exosomes [111]. BALF exosomes from sarcoidosis patients are also enriched in pro-
inflammatory molecules and increase cytokine release from PBMC, indicating that these 
exosomes may participate in disease progression [112]. The first report of exosome secretion 
by eosinophils showed that more vesicles are released by eosinophils from asthmatic patients 
compared to healthy donors [113]. 
Tumor derived exosomes participate in maintaining the tumorigenic milieu through several 
routes. For example, due to their immunomodulatory properties, tumor exosomes support 
immunosuppression, by impairing dendritic cells maturation and promoting Treg activation; 
they also modulate the TME directly, by enhancing angiogenesis and promoting the 
formation of favorable metastatic niches, all to support the tumor growth [114]. The ’seed 
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and soil’ theory postulates that metastatic spread of cancer cells is not random but tightly 
regulated, and requires compatibility between disseminated malignant cells and 
microenvironment so that new metastatic loci can form [115]. It is now recognized that 
exosomes are among the factors that prepare a favorable TME, the soil, thus promoting 
metastasis formation initiated by circulating cancer cells, the seed [116]. In a lung cancer 
model, it was recently demonstrated that tumor derived exosomes promote metastasis by 
directly activating TLR-3 in alveolar epithelium, resulting in neutrophil recruitment [117]. 
Also TLR-8 is involved in lung tumorigenesis: lung cancer exosomes contain miRNAs that 
activate macrophages via TLR-8 to secrete pro-inflammatory and tumorigenic cytokines, 
such as TNFα and IL-6 [118]. Recruitment of macrophages is a fundamental step in 
establishing the TME: lung cancer exosomes induce mesenchymal stem cells (MSC) with an 
inflammatory phenotype which secrete cytokines such as MCP-1, the most potent 
macrophage chemoattractant, resulting in their higher infiltration and larger tumors in 
comparison to unstimulated MSC [119]. Lung cancer exosomes, especially when released in 
hypoxic conditions, can promote vascularization and at the same time vascular permeability, 
which is a crucial step to allow infiltration of tumor supporting cells [120]. Exosomes also 
promote EMT: notably, serum derived exosomes from lung cancer patients induce expression 
of vimentin as well as migration of healthy bronchial epithelial cells [121]. Since exosomal 
cargo (miRNA and proteins) mirrors parental cells, these vesicles have been suggested as 
diagnostic biomarker candidates in disease. For example, the concentration of plasma 
exosomes and their total miRNA amount in patients with lung adenocarcinoma is higher 
compared to control groups, and elevated levels of miRNAs associated to lung tumor tissue 
were also detected in the exosomes of patients, strengthening the use of exosomes as 
diagnostic tools in lung cancer [122]. A more recent study further support the use of 
exosomal miRNA as diagnostic marker in lung carcinogenesis [123].  
 
Chapter 3.3 Eicosanoids & exosomes 
Eicosanoids and exosomes represent two different types of messengers. Eicosanoids are 
hormone-like compounds, acting via G-protein coupled receptors on target cells, which are 
normally neighboring cells, since these lipid mediators have a short half-life. On the other 
hand, exosomes are large vesicles containing a selected cargo, which could exert a multitude 
of effects and functions, as such or after uptake into cells. Some organ-derived exosomes 
retain their specificity: intestine derived exosomes are taken up mainly by the intestine itself 
within 24 hours, and only a prolonged circulation will lead to clearance by other organs, 
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mainly liver [124]. Malignant exosomes isolated from cancer cell lines appear to be taken up 
mainly by liver and spleen [125] but tumor derived exosomes can also travel to specific 
niches, notably lung and liver, to promote metastasis formation, a phenomenon dictated by 
the expression of specific integrins [126]. Moreover, if not cleared immediately, exosomes 
are quite stable in body fluids, and they protect their content. For example, free miRNA in 
circulation is more vulnerable to ribonucleases in comparison to exosomes-carried miRNA, 
suggesting the higher validity as biomarker resource of the latter type [127]. This is true also 
for compounds of different nature: exosome-bound curcumin, a potent cPLA2/COX/5-LO 
inhibitor [128] displayed longer bioavailability in vivo and enhanced anti-inflammatory 
properties in comparison to free curcumin [129], suggesting that exosomes may be exploited 
as specific and efficient drug delivery systems [130]. 
Rather than being two parallel ways for cells to communicate, exosomes and eicosanoids 
often converge, with the first behaving as a tool box for the second. For example, exosomes 
are enriched in phospholipids, ceramides and cholesterol but they also carry PUFAs, mainly 
AA and LA [131]. Furthermore, depending on the parental cells, exosomes may carry 
enzymes involved in the different steps of AA. PLA2 members including iPLA2, sPLA2 and 
cPLA2, responsible for the cleavage of PUFA from membrane phospholipids, have been 
detected in mast cells derived exosomes; surprisingly, these enzymes showed functional 
activity via a GTP-dependent mechanism, an unknown pathway in the cellular system [131]. 
Other active enzymes involved in the AA metabolism have been detected in the same 
exosomes, such as COX-1 and COX-2 [131]. Transcellular biosynthesis of AA metabolites is 
a well-described process, and exosomes can function as substrate supplier in the local or 
distant microenvironment. Due to their ability to transport active enzymes, exosomes may 
also participate in the transcellular biosynthesis as ‘nanocells’. For example, macrophages 
and dendritic cells express enzymes involved in the biosynthesis of LTs and also secrete 
exosomes loaded with LTC4s and LTA4h, but apparently less 5-LO. Moreover, exosomal 
LTC4s and LTCA4h metabolize LTA4 more efficiently compared to the parental cells, and 
their contribution to LT biosynthesis may explain the ability of the exosomes to induce 
PMNL chemotaxis [132]. Majumdar et al demonstrated that also exosomes released by 
PMNL carry 5-LO, FLAP and LTA4h. After fMLP stimulation these vesicles are directly 
loaded with LTB4 and can efficiently promote PMNL migration in a LTB4-BLT1 manner 
[133]. LTA4h is also packed in exosomes isolated from BAL fluid of sarcoidosis patients, 
and so are 5-LO and FLAP [134]. Exosomes from BAL fluid of asthma patients have higher 
LTA4h activity compared to LTC4s activity; in comparison to exosomes from healthy 
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donors, exosomes from patients also induce increased LTs formation and IL-8 release in 
bronchial epithelial cells [135]. 
Remarkably, exosomes have also been reported to carry bioactive lipid molecules directly, 
such as prostaglandins. Regarding tumor progression, breast cancer derived exosomes are 
enriched for PGE2 and when injected in mice they induce accumulation of myeloid derived 
suppressor cells (MDSC), and release of pro-inflammatory cytokines such as IL-6 and 
VEGF, thus promoting tumor growth [136]. In the tumor micro-environment MDSC are 
capable of differentiating in macrophages, further enlarging the population of tumor 
associated macrophages (TAM), fundamental contributors to tumorigenesis [137]. Exosomes 
pretreated with anti-PGE2 antibodies displayed a partial decrease in MDSC induction and 
cytokines release, suggesting that exosomal PGE2 may favor the creation or maintenance of 
the tumorigenic milieu [136]. Intestinal exosome-like particles also carry PGE2, which 
mediate, in part, the anergic state of natural killer T cells in the liver, where these vesicles 
migrate and where they may play a pivotal role in the liver immune system [124]. 
 
Chapter 4. Macrophages, polarization and cancer 
Phagocytosis evolved as a mechanism for nutrition in primitive unicellular organisms, but in 
multicellular organisms this process turned into a system for protection [138]. Today, 
macrophages represent the first defense line of phagocytes in vertebrates and play a crucial 
role as sentinels of the immune system in response to pathological events that may trigger 
inflammation in tissue [139]. The origin of macrophages has been vastly investigated: tissue 
resident macrophages originate from the yolk sac and the fetal liver; during inflammation, 
peripheral blood monocytes derived from bone marrow will be recruited and differentiated to 
macrophages in the inflamed tissue [140]. Macrophages can recognize harmful stimuli, 
destroy them and communicate with the surrounding environment to restore physiological 
conditions. In the year 2000 Mills proposed for the first time the M1/M2 polarization concept 
in relation to Th1/Th2 response [141], providing a simple model to better understand the role 
of macrophages. Their function is far more heterogeneous compared to T cells: it depends on 
the broad range of stimuli that can activate them and shift their phenotype within a broad 
spectrum, delimited by pro-inflammatory and healing/resolving functions (Figure 5) [142, 
143].  
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Figure 5. Schematic representation of the most common stimulating factor, type of function, 
and markers that characterize M1/M2 macrophages 
 
One of the most important discoveries that pushed research on M1/M2 polarization arouse 
when M2 macrophages were shown to promote cancer [144]. TAMs are formed mainly by 
recruited monocytes [145], as demonstrated also in a mouse model for lung cancer [146]. 
TAMs are fundamental supporters of tumorigenesis and the majority of them exhibit typical 
markers of M2 polarized cells [147, 148]. In 1998, a few years before the concept of M1 and 
M2 polarization would storm into the macrophages research, Huang et al demonstrated that 
macrophages grown in presence of supernatant from lung cancer cells increased IL-10 
production and decreased IL-12 production [149]. Today these two cytokines are considered 
specific M2 and M1 markers [150], and is well known that cancer cells can turn macrophages 
toward M2 [151]. In the same paper, Huang et al demonstrated that the factor released by 
cancer cells that shifted the cytokine profile from M1 to M2 was PGE2 [149]. PGE2 has 
indeed a tight connection with cancer and macrophages. For example, PGE2 can promote 
tumorigenesis also by enhancing TAM's expression of PD-L1, thus polarizing them toward 
an immunosuppressive M2 phenotype [152].  Doxorubicin resistant breast cancer cells also 
release PGE2 to expand an M2 polarized population of MDSC [153]. This is in agreement 
with a celecoxib (COX-2 inhibitor) treatment in a mouse model with lung cancer, where 
blocking of PGE2 signaling inhibited tumor growth by increasing M1 and decreasing M2, 
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thus changing the M2/M1 ratio [154]. The overall tissue M2/M1 ratio observed in tumor 
tissue of NSLCC lung cancer patient is close to 70:30; however, higher M1 density in tumor 
islets positively correlated with patient survival time [155]. Similar results were obtained in 
another study: infiltrating TAMs in tumor specimens from patients with lung adenocarcinoma 
show a M2 phenotype, and higher % of M2 correlated with poor survival [156]. So far, 
targeting M2 or reprogramming these cells toward M1 appears as a possible therapy against 
cancer. For example, in a melanoma model, antibody therapy against the receptor MARCO 
expressed by M2-like but not M1-like macrophages resulted in reduced tumor growth and a 
shift toward M1 populations. This was one of the first studies to demonstrate successful 
immunotherapy based on TAM reprogramming as tool to treat cancer [157]. Ablation of 
dicer, the miRNA processing enzyme, is another approach that results in inhibition tumor 
growth, caused by enrichment of M1 macrophages whereas M2 macrophages are shut down 
by dicer inactivation [158]. Zanganeh et al also reported that activation of M1 macrophages 
by iron oxide nanoparticles could inhibit primary tumor growth, and lung and liver metastasis 
in a mammary tumor mouse model [159]. All these studies support M1 reprogramming as a 
therapy against malignant cancer. However, the tumor heterogeneity is a crucial factor to 
consider [160] and it is important to point out that tumor infiltrating macrophages are never 
made by M2 macrophages only, as mentioned earlier [155, 156]: this raises the question 
whether the M1 infiltrating cells are the last defense line of the immune system, still fighting 
against the tumor itself. However, there may be the possibility that a small but significant 
percentage of M1 actually may contribute to tumorigenesis, given their higher ability to form 
pro-tumorigenic molecules such as IL-6 [150], which in turn can promote M2 polarization 
[161]. M1 macrophages also release larger amounts of PGE2 [162], which can effectively 
promote M2 polarization as mentioned above.  
Another complex issue is the contrasting nature of the TME, immunosuppressive and yet 
inflammatory, tightly linked to TAMs. Smoke and chronic inflammation are well known 
contributors to lung cancer and COPD patients have a higher risk in developing lung cancer 
[163]. COPD patients present high and prolonged expression of NF-kB [164], resulting in 
immunosuppression supported by the presence of Tregs and M2 macrophages [165]. SPM 
are investigated as therapy for chronic inflammation, also in light of their potential to 
modulate macrophages polarization. For example, RvD1 treatment promotes M2 polarization 
resulting in a reduced neutrophilic lung inflammation in a mouse model of smoke-induced 
lung inflammation [166]. Similarly, other studies demonstrated that resolvins promote M2 
polarization [167, 168]. It is reasonable that M2 macrophages sustain their phenotype in a 
positive autocrine loop, in light of their effective endogenous SPM biosynthesis,  in 
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comparison to M1 macrophages [162]. However, recently it was reported that SPM such as 
RvD1, RvD2 and Maresin 1 can also regulate adaptive immunity and induce 
immunosuppression by enhancing Treg and decreasing CD8 and CD4 T cells activity [169]. 
It is plausible that a constant attempt to resolve dysregulated inflammation actually initiate 
immunosuppression in the TME, thus creating a favorable tumor milieu. Consequently, a 
deeper understanding of the eicosanoid/macrophage networking is required in order to use 
macrophage polarization for effective therapies. 
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MATERIALS AND METHODS 
The following studies were performed according to the ethical guidelines at Karolinska 
Institute, with approved ethical permits for Paper I and Paper III. 
 
Detailed information on material and methods can be found in the respective papers. Here 
is presented a brief list of the performed methods.  
 
 
 
Paper 
I 
Paper 
II 
Paper 
III 
Cell culture (MM6 cells, MDMs, MDDCs, Eosinophils, A549 
cells, PBEC, primary lung cancer cells) x x x 
Handling of human pleural exudates     x 
Exosome isolation from culture supernatants and pleural exudates x   x 
Western blot analysis x x x 
Cell incubations and solid phase extraction of lipid mediators x x x 
High performance liquid chromatography (HPLC) x x x 
Mass spectrometry analysis x x x 
Flow cytometry analysis x x x 
Enzyme-linked immunosorbent assay (ELISA)   x x 
Immunocytochemistry x x   
Viability assay     x 
Scratch assay     x 
Exosome size analysis by Nanosight x   x 
Sucrose gradient fractionation     x 
Electron microscopy     x 
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PAPERS 
Paper I: the co-culture project  
Background and aim 
Asthma is an obstructive lung disease, characterized by chronic inflammation [51], and  the 
global frequency has been increasing since the '70 [170]. AERD is considered a subtype of 
asthma that develops in response to NSAID treatment, which results in COX inhibition and a 
consequent shunt of AA toward other pathways, mainly LOs [171]. In fact, patients with 
AERD present higher expression of LTC4s [172] and overproduction of CysLTs, sustained 
by platelet-adherent leukocytes [173]. The increased formation of inflammatory CysLTs may 
not depend only on higher availability of AA but also on regulatory mechanisms. Inhibition 
of COX results in decreased PGE2 formation, which can directly regulate LTs formation, via 
cAMP-PKA catalyzed phosphorylation of serine-523 on 5-LO [174]. Also, it was shown that 
prolonged exposure to zymosan, a TLR-2 agonist, results in decreased LTC4s activity in 
monocytes; this inhibitory phosphorylation depends on endogenous PGE2 formation and can 
be counteracted by aspirin treatment [175].  
In vitro experiments normally investigate a single cell type and this is a major limit compared 
to in vivo models. Co-culture systems represent an upgrade, allowing researchers to 
investigate biological events considering cells interactions [176, 177]. A549 is an alveolar 
type II epithelial cell line established from a lung cancer patient, widely used as in vitro 
model for lung epithelial cells. This cell line is also exploited as a valid substitute for lung 
epithelial cells in co-culture models that mimic the interaction between lung epithelium and 
macrophages [178-183]. Inspired by a previous study on PGE2-LTC4s regulation within 
macrophages [175], we aimed to understand if also PGE2 from the lung epithelium could 
regulate LTC4s activity in monocytes/macrophages. 
 
Results and discussion 
 We selected Mono Mac 6 (MM6), a leukemia-derived macrophage-like cell line, to combine 
with A549 in a co-culturing system. This represents a valuable model for our study, given the 
possibility to regulate both 5-LO in MM6 and mPGES1 in A549 [184, 185]: in fact, MM6 
cells were treated with TFG-β and Vitamin D3, to upregulate 5-LO expression and activity, 
while A549 cells were stimulated with IL-1β, in order to increase PGE2 production. Finally, 
cells were co-cultured for 24 hours and further experiments were performed. LT biosynthesis 
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assays showed that monocultures of MM6 cells produced mainly LTC4, while A549 cells 
could not produce LTs from AA (Figure 2, Paper I). Importantly, there was no detectable 
change in the formation of LTC4 from exogenous LTA4 or endogenous AA when MM6 were 
co-cultured with A549 for 24 hours. Although IL-1β clearly upregulated mPGES1 in A549 
cells as observed by western blot, the concentration of PGE2 in the co-culture medium was 
~3-5 nM, as measured by LC-MS.  Apparently, this was not sufficient to modulate LTC4s in 
MM6. However, the co-culture did show a significant change: formation of LTD4, which was 
almost undetectable when both cells were grown in monocultures.  
The formation of LTD4 is relevant for several reasons: here we mimic the lung 
microenvironment, where LTD4 exert important functions in asthma, as the most potent 
agonist of CysLT1. Moreover, A549 is a cancer cell line but in lung cancer a specific effect 
of LTD4 has not been described. On the other hand, increasing evidence over the last two 
decades demonstrated the pro-tumorigenic effect of LTD4 in colon cancer [186]. In detail, 
several colon cancer cell lines form CysLTs [187, 188], which may further promote survival 
of cancer cells via CysLT1 [187]. Moreover, higher expression of CysLT1 correlates with 
poor prognosis in colon cancer patients, similarly to COX-2 overexpression [189]. 
Interestingly, LTD4 but not LTC4 upregulates COX-2 expression in intestinal epithelium 
[190] and the positive effect of LTD4 on COX-2 expression was shown also for  malignant 
intestinal epithelial cells [188, 191]. 
Given the established functions of LTD4 in the lung and in cancer, we further investigated 
LTD4 formation in our model. LTC4 must be exported to be converted to LTD4: once 
exported LTC4 can access GGT, a plasma membrane protein that convert GSH and LTC4. 
Activity assays with different substrates and western blots (Figure 2-3, Paper I) indicated that 
MM6 cells produced and exported LTC4 (Table 1, Paper I), which was further converted by 
A549 cells via GGT-1 in a transcellular manner. A549 cells formed LTD4 quickly and more 
efficiently upon IL-1β stimulation (Figure 4, Paper I).  It was previously shown that 
macrophages and dendritic cells exosomes carry active LTC4s and LTA4h [132] and we 
hypothesized that exosomes could also carry active GGT-1. Indeed, when MM6 cells were 
incubated with LTA4 in presence of A549 derived exosomes, more LTD4 was produced, due 
to GGT-1 present in exosomes (Figure 5, Paper I). We also treated the co-cultures with Serine 
Borate complex (SBC), an inhibitor of GGT-1 to confirm that LTD4 is truly formed via this 
protein: SBC treatment blocked LTD4 formation, and unexpectedly it also upregulated 5-LO 
activity in MM6 cells, allegedly by increasing the nuclear translocation of 5-LO.   
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Increased formation of LTD4 was also observed in short time co-incubations of A549 cells 
with monocyte-derived dendritic cells and with eosinophils, while these cells alone formed 
LTC4 and almost no LTD4 (Figure 6, Paper I). A deeper investigation in literature confirmed 
that most leukocytes lack the capacity to form all CysLTs: in the majority of studies mainly 
LTC4 had been detected, as we also observed with MM6. Not only monocytes/macrophages 
[192-194], but also eosinophils [195-197] and mast cells mainly form LTC4 [198-200]. 
Interestingly, when MM6 were incubated with primary bronchial epithelial cells (PBEC), 
longer time was required to obtain a significant increase in LTD4 formation. Further 
investigation showed that PBEC form LTD4 via GGT-5, another member of the GGT family, 
which converts LTC4 slowly compared to GGT-1 (Figure 7, Paper I). While the gene family 
for GGT includes several members [29], only two of these are LTD4 producing enzymes, 
GGT-1 and GGT-5. In vitro data on purified human GGT-1 and GGT-5 showed that both 
enzymes have similar affinity for LTC4 but the first converts LTC4 faster, indicating a more 
active “leukotrienase” activity [30]. In co-incubations of MM6 with the normal PBEC 
(expressing GGT-5) a long incubation time (6 hours) was required for substantial conversion 
of LTC4 to LTD4, while co-incubations of MM6 with A549 cells (expressing GGT-1) 
produced comparable amounts of LTD4 within 30 min: this demonstrated that human GGT-1 
has the highest LTD4 forming activity both as purified protein and in whole cells.   
In conclusion, this study elucidated the differences between GGT-1 and GGT-5 in LTD4 
formation on a cellular level. Our model indicates that myeloid derived cells produce and 
donate LTC4 and that pulmonary epithelium, normal and malignant, can transform LTC4 to 
LTD4. These results emphasize an active role of epithelial cells and their exosomes in the 
biosynthesis of LTD4, a fundamental eicosanoid in pulmonary inflammation.  
 
Future plans 
It is well known that CysLTs may be formed in a trans-cellular manner. For example. 
neutrophils form and export LTA4, which can be converted to LTC4 by platelets [201]. 
Alveolar macrophages and lung epithelium can exchange AA and enhance 5-LO or COX 
derived products [72]. Given the intricate nature of AA metabolism, and the  knowledge that 
several enzymatic steps follow a transcellular route [202], it is vital to understand the function 
of each player.  Administration of drugs, systemic or locally, lack the ability to target a 
specific cell type. Liposomes and exosomes are investigated as cell specific-delivery systems, 
which may become feasible in the next future [203].  Therefore, it is fundamental to resolve 
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all the metabolic steps that a complex cellular network may exploit to form eicosanoids. Co-
culture models with multiple players, such as leukocytes-epithelial-endothelial cells, may 
provide more clear pictures of how single cell types contribute to eicosanoid biosynthesis, 
thus indicating the most suitable drug-target.  
When MM6 cells were incubated for 30 min with LTA4 in presence of exosomes, we 
detected LTD4, formed via GGT-1 packed within the vesicles. However, when MM6 cells 
were incubated with LTA4 after 24 hours treatment with exosomes, no LTD4 was formed 
(data not shown); instead, MM6 showed a decreased 5-LO activity, with both endogenous 
and exogenous AA. Studies exploiting co-culture models can expand our knowledge on how 
exosomes regulate the eicosanoid biosynthesis and metabolism, given that this 
communication channel can easily be manipulated. MiRNA and proteins delivered by 
exosomes may retain their function in recipient cells. For example PTEN, a tumor-
suppressant protein, can be transported between cancer cells via exosomes [204]. We know 
that cells take up exosomes and can further process/sort the exosomal content [205, 206]. Our  
data indicate that MM6 did not retain the exosomal GGT-1 activity. The other way around, in 
a pilot experiment we observed that MM6 derived exosomes could deliver 5-LO to THP-1, 
an immature-macrophage like cell line, but this transfer did not occur when the recipient cells 
were A549 cells. These preliminary results raise the question: which component of the 
eicosanoid metabolic cascade can be transferred between cells? Enzymes and receptors of the 
eicosanoid cascade are not ubiquitous: if exosomes contain these proteins, a spontaneous 
question is whether this packing is just a tool to shed unnecessary functions or if it might be a 
mechanism to increase and disseminate formation of eicosanoids.  
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Paper II: the macrophage project 
Background and aim 
Blood derived monocytes are the main resource to obtain differentiated macrophages in vitro, 
induced by GM-CSF or M-CSF and in previous projects in the group one or the other of these 
cytokines have been used [15, 132]. In a pilot experiment we compared macrophages 
differentiated with both cytokines and we observed a significant difference in the ability to 
form 5-LO products. GM-CSF and M-CSF prime macrophages toward the two end points of 
the broad spectrum of macrophage phenotypes, M1 and M2 respectively, but without fully 
reaching these [142, 207]. Specific transcripts differentiated between M1 and M2 
macrophages include enzymes involved in eicosanoid metabolism [208] and the lipidomic 
profile of these two phenotypes indeed shows significant differences: for example, M1 
macrophages  release higher amounts of inflammatory PGs and LTs, while M2 macrophages  
release higher amounts of LXs [162]. These lipid signatures are in agreement with the 
commonly accepted concept that M1 are  pro-inflammatory macrophages while M2 are 
resolving macrophages [142]. 
The M1/M2 concept applies mainly to in vitro models and it does not take in account the 
kinetics of the different pathways and mechanisms exploited by macrophages to orchestrate 
the inflammatory process, from the earliest onset to the resolution phase [209]. The time 
course of inflammation is normally simplified in few specific phases, delimited by initiation 
and resolution [1]. In vitro activation and polarization of macrophages normally requires 18-
24 hours of stimulation, in order to induce transcriptional changes [150].  Considering the 
time required to activate macrophages, this means that in vitro generated M1 and M2 
macrophages can be placed somewhere in the middle or late phase of an ongoing 
inflammatory processes. However, eicosanoids are products of pre-existing enzymes that can 
be activated within minutes; in fact, these mediators are produced during all phases of 
inflammation, from the earliest stage to the latest resolving phase. This means that studies on 
fully activated M1 and M2 macrophages fail to observe differences in eicosanoid metabolism 
that arise in the onset of inflammation, when bacterial alarm signaling triggers the immune 
response and the consequent phenotypic shifts. Lipidomic analysis has been successfully 
applied to study the modulation of AA metabolism, and several papers have been published 
for mouse derived macrophages [193, 194, 210, 211]. However, only one comprehensive 
report was published for human M1/M2 macrophages [162] and  formation of lipid mediators 
in GM/M-CSF primed macrophages, the earliest inflammatory phase, had not been 
investigated. The study described in Paper II aimed to fill in this gap.  
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Results and discussion 
We differentiated human monocytes with GM-CSF or M-CSF and after 7 days, we obtained 
primed but not fully polarized M1 and M2 cells (Figure 1, Paper II). We then determined by 
LC-MS/MS the eicosanoid and other lipid mediators released from resting cells, and 
produced upon short (30 min) bacterial stimulation. We chose LPS/fMLP and peptidoglycan 
(PGN), both physiological stimuli representative of Gram- and Gram+ infection. During the 
last 24 hours of differentiation, resting M-CSF macrophages released more anti-inflammatory 
LXA4 (Figure 2, Paper II), similarly to M2 macrophages [162]. Basal formation of PGs was 
comparable between GM-CSF and M-CSF macrophages (Figure 2, Paper II), in contrast to 
published data, reporting that PGs release is higher in M1 in comparison to M2 [162, 212]. 
Resting GM-CSF cells released more CYP derived products: EETs metabolites are generally 
regarded as anti-inflammatory [213], however we detected mainly the inactivated DHETs 
form, derived from further metabolism by sEH. 
We also characterized for the first time the eicosanoid pathway in human macrophages in 
response to short bacterial stimulation. M-CSF macrophages released larger amounts of 5-LO 
products, particularly following LPS/fMLP stimulation (Figure 3, Paper II). Specifically,  M-
CSF macrophages shunted the intermediate LTA4 to LTC4s rather than to LTB4h. Asthma is 
generally considered a Th2 type disease [214], associated with M2 accumulation [215]. M-
CSF macrophages display considerably higher LTC4 production in line with priming to M2, 
associated to asthma where release of CysLTs exert crucial  functions, particularly as 
modulators of bronchoconstriction and tissue remodeling [16]. Interestingly, conversion of  
AA to 15-HETE, catalyzed by 15-LO, was about 20 times lower compared to 5-HETE 
formation. The total amount of COX-derived metabolites showed minor differences between 
the two phenotypes (Figure 3, Paper II), in agreement with comparable levels of COX-1 
expression between GM-CSF and M-CSF macrophages (Figure 4, Paper II) and both 
macrophages phenotypes released a negligible amount of CYP products. We also detected 
17-HDoHE, precursor of resolvins, and other anti-inflammatory mediators (Figure S2, Paper 
II). These were all more abundant in M-CSF MOs, in agreement with the higher ability of M2 
macrophages to release pro-resolving mediators [162].  
Differentiation with GM-CSF or M-CSF was not sufficient to induce COX-2, which accounts 
for a large part of PGs biosynthesis in M1 macrophages, obtained by long-term stimulation 
with IFN-γ and/or LPS [5, 208]. However, GM-CSF and M-CSF differentiation was 
sufficient to modulate the protein expression of other eicosanoid forming enzymes. 
Expression of cPLA2, 5-LO and FLAP was significantly higher in GM-CSF cells (Figure 4, 
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Paper II). Literature on 5-LO in M1 and M2 macrophages is contrasting: Lehmann et all 
reported similar results for 5-LO/FLAP expression in M1 and M2, in agreement with our 
findings for GM-CSF and M-CSF macrophages [216]. In contrast, others have shown that 
ALOX5, the gene encoding 5-LO, was downregulated more prominently in M1 compared to 
M2 [208, 212]. Transcriptome levels do not always compare to protein levels [217] and 
possibly transcriptional changes in ALOX5 require longer time to translate to changes in the 
expression of 5-LO protein. M-CSF macrophages expressed higher levels of 15-LO (Figure 
3), in line with reports for M2 [208, 212].  
The most prominent mismatch between protein expression and effective metabolic activity 
was observed for the 5-LO pathway: the protein expression of 5-LO was significantly higher 
in GM-CSF macrophages. Our findings suggest that M-CSF macrophages could overcome 
the lower 5-LO protein expression and release larger amounts of LTs by enhanced activation 
and mobilization of key enzymes, cPLA2 and 5-LO, in response to bacterial stimulation 
(Figure 5). In line with several publications on CysLTs in monocytic cells (see Paper I), only 
10% of LTC4 was further metabolized to LTD4, in both M-CSF and GM-CSF macrophages, 
via GGT-5 (Figure 4, Paper II). However, this was surprising since GM-CSF macrophages 
displayed a clear western blot band for GGT-1 (Figure 4, Paper II).  
Tissue resident macrophages are among the first cells to sense alarm signals. They respond, 
and orchestrate the immune response by recruiting neutrophils and additional macrophages 
during progression of inflammation. M-CSF is constitutively expressed and its depletion 
leads to reduction of several tissue resident macrophages populations while GM-CSF is 
known to be increased during inflammation. In fact, macrophages differentiated with the M-
CSF in vitro are close to normal homeostatic macrophages while macrophages differentiated 
with GM-CSF are considered inflammatory macrophages [218]. Resident macrophages need 
to respond quickly, including mobilization of endogenous substrate when bacterial 
stimulation triggers the immune response: here we did observe that M-CSF macrophages 
mobilized AA more efficiently compared to GM-CSF macrophages (Figure 5, Paper II), 
despite lower expression of cPLA2 (Figure 4). This is in agreement with a recent report: bone 
marrow derived macrophages also release larger amounts of AA when polarized toward the 
M2 endpoint [219]. The M-CSF cells here investigated  also released larger amounts of 
CysLTs, known to increase vascular permeability, a key event during early inflammation 
[220]. Similarly, tissue macrophages of murine origin showed preference for LTC4 when the 
5-LO cascade is triggered [193, 194, 219]. Moreover, resemblance of M-CSF macrophages to 
tissue macrophages agrees with an M-CSF priming toward the M2 state, since steady state 
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macrophages in homeostatic conditions should be closer to the reparative/resolving endpoint, 
than to the inflammatory end of the spectrum. On the other hand, GM-CSF release is 
augmented during inflammation. Other leukocytes recruited to the inflamed tissue, such as 
neutrophils and platelets, can deliver free AA [202]. When such exogenous substrate is 
provided, GM-CSF macrophages can exploit more efficiently the higher expression of the 
enzymatic machinery behind LTs productions, as we showed when cell were incubated with 
exogenous AA (Figure 5, Paper II) and thus contribute to amplify the ongoing inflammation.  
In conclusion, we report for the first time a comprehensive eicosanoid analysis in human 
GM-CSF and M-CSF differentiated macrophages. GM-CSF and M-CSF alone can prime 
macrophages for specific lipid metabolism, demonstrating that polarization toward M1 and 
M2 has started. However, full activation is fundamental to exploit all components of the 
eicosanoid metabolism, notably COX-derived products. Moreover, the distinct eicosanoid 
profiles in response to bacterial stimulation do not reflect protein expression but rather the 
efficiency to activate eicosanoid-forming enzymes.  
 
Future plans  
Inflammatory conditions are promoted by several factors. Among these are Pathogen-
Associated Molecular Patterns (PAMPs) [221] and alarm molecules of endogenous origin, 
called Damage-Associated molecular patterns (DAMPs) [222]. DAMPs, for example ATP 
and DNA, are often released by cancer cells and may contribute to inflammation in the tumor 
micro-environment [223]. Here we observed distinct lipid metabolism when macrophages 
were stimulated with LPS/fMLP or PGN, which can be identified as PAMPs. So far, there is 
no clear evidence on how DAMPs may affect eicosanoid metabolism in macrophages. A 
comprehensive lipidomic analysis of macrophages stimulated with tumor associated DAMPs 
may unveil how eicosanoid formation is modulated by the TME.  
The immunity of lymphocytes, and their crosstalk with macrophages, notably via cytokines, 
inspired the M1/M2 notion; however, depletion of lymphocytes does not block M1 and M2 
generation [141]. Recent studies [224-227] suggest that eicosanoids may also contribute to 
the phenotypic shift of macrophages during inflammation, given the early activation of this 
metabolic cascade and the ability of eicosanoids to modulate cytokines and other immune 
molecules [58, 228, 229]. Therefore, further research may clarify how eicosanoids contribute 
to the development of M1/M2 phenotypes. Intervention on the eicosanoid cascade during 
activation of macrophages may block the phenotypic shifts associated with diseases like M2 
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in asthma [215] and cancer [137] and M1 in obesity [215, 230], thus providing an additional 
therapeutic tool based on macrophage manipulation. 
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Paper III: the pleura exudate project 
Background and aim 
In Paper I we showed that myeloid cells and bronchial epithelial cells transform LTC4 to 
LTD4 slowly, via GGT-5. On the other side, the lung cancer cell line A549 formed LTD4 
quickly, via GGT-1. A rapid formation of LTD4 by the malignant cells raises the question 
whether CysLTs have a function in lung cancer. The pro-tumorigenic effect of the LTD4-
CysLT1 cascade in colon cancer is well established [186]. However, recently it was 
demonstrated that LTC4 execute anti-tumor effects via CysLT2, by upregulating 15-PGHD, 
the enzyme that promotes catabolism and inactivation of PGE2 [231]. This suggests that a fast 
conversion of LTC4 is crucial to promote tumorigenesis, highlighting the function of GGT-1 
as the fast LTD4 forming enzyme. GGT-1 is a well established marker for hepatic diseases, 
including liver cancer [232, 233]. It plays a crucial role in redox regulation and it has been 
linked to oxidative stress and chemoresistence in cancer [234, 235]. However, little is known 
about GGT-1 and lung related diseases. In the lungs, GGT-1 and GGT-5 are detected mainly 
in alveolar macrophages [28, 236].  An aberrant expression of GGT-1 is found in specimens 
from patients with lung cancer, mainly adenocarcinoma [237, 238]. A recent epidemiological 
study demonstrated that higher serum levels of GGT-1 correlate with specific types of 
cancers, including stomach, colon and lung [239]  and GGT-1 activity might be exploited to 
visualize small tumor loci in the lungs [240]. In paper I we observed that GGT-1 is the fastest 
LTD4 forming enzyme and we also showed exosomes from the NSCLC cell line A549 form 
LTD4 via GGT-1. Several reports unveil the function of exosomes in lung tumorigenesis 
[114, 117-121] and exosomes of malignant (prostate) origin carry active GGT-1 [241]. In 
paper III we investigated the link between GGT-1, LTD4, exosomes and lung cancer using 
biological specimens from patients with lung cancer.  
 
Results and Discussion 
In collaboration with the Department of Respiratory Medicine and Allergy, Karolinska 
Hospital Solna, we obtained pleural exudates (PE) from 14 patients with lung cancer. From 
these PEs we isolated exosomes and malignant cells for further studies (Figure 1-2, Paper 
III), as previously shown [242, 243]. Both PE-derived exosomes and malignant cells 
contained GGT-1 and rapidly formed LTD4 (Figure 3, Paper III). In contrast to macrophages 
and dendritic cell derived exosomes, PE-exosomes did not form any LTC4 or LTB4 when 
incubated with LTA4 (data not shown) but did form LTD4 from LTC4 similarly to A549 
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exosomes, suggesting that epithelial/cancer cell exosomes are different from antigen 
presenting cell exosomes in terms of LT biosynthesis. Moreover, malignant cells from 9 out 
of 12 patients were positive for GGT-1, further suggesting that this protein may indeed be a 
valid marker for lung adenocarcinoma [239, 240].  
We performed LC-MS analysis on PEs, and on resting and stimulated cancer cells. Although 
PE-derived cancer cells express the enzymes to form LTs, only few pg of CysLTs were 
formed while the most abundant metabolites were PGs: we detected 37 ng/10
6
 cells of PGE2  
in cell culture medium and over 53 ng/10
6
 cells in presence of exogenous AA. On the other 
hand, these cells could form over 28 ng/10
6
 cells of LTD4 when exogenous LTC4 was 
provided, in the same range of PGE2 biosynthesis. We also detected 22 pg/ml of PGE2 and 17 
pg/ml of LTD4 in the original PE used to establish the cancer cells (Table S2, Paper III). We 
believe that the similar amounts detected in the PEs, which can be considered very close to in 
vivo, suggest that PGE2 and LTD4 equally contribute to lung tumorigenesis. There may be 
several advantages for the cancer cell to release high amounts of both mediators. For 
example, LTD4 can directly promote PGE2 formation by increasing COX-2 expression in 
colon cancer cells [188] and both mediators promote tumor growth in a colon cancer model 
[244]. Moreover, PGE2 and LTD4 cooperate to promote vascular inflammation [245], which 
may promote formation of pleural effusions [246]  
The drastically different capacities of lung cancer cells to form LTC4 from AA, compared to 
the conversion of LTC4 to LTD4, raises the question which other cells may donate LTC4 in 
the TME. We isolated macrophages from PE in parallel to malignant cells: when endogenous 
metabolism of AA was stimulated with A23187, PE-derived macrophages formed high 
amounts of LTs, and more LTC4 than LTB4, similarly to M-CSF macrophages, as determined 
in Study II. TAM are leukocytes that infiltrate the TME and promote tumorigenesis [148]. 
Their phenotype shifts between M1 and M2 endpoints, but a higher percentage of M2 is 
associated with poor prognosis in patients with lung cancer [156]. Given the similar LT 
formation of PE-derived macrophages as in M-CSF macrophages, which are primed toward 
the M2 phenotype, we believe that M2-polarized TAM represent an ideal resource of LTC4 in 
the TME. Other effective candidates to form LTC4 in the TME are exosomes of myeloid 
origin. As we mentioned before, neutrophils are enriched in the TME [247]. So far, 
neutrophils are considered the best donors of LTA4, given their ability to export over 50% of 
it [32]. Exosomes released by macrophages and dendritic cells efficiently convert LTA4 to 
LTC4 [132]. Thus, we believe that TAM and myeloid-derived exosomes may contribute to 
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cancer progression by providing the LTC4 that malignant exosomes and cells convert to 
LTD4. 
Since both exosomes and eicosanoids can promote a pro-tumorigenic environment, we 
investigated the effect of PE-derived exosomes on the eicosanoid metabolism in PE-cancer 
cells by LC-MS/MS. Malignant cells increased the formation of CysLTs after 24 hours 
treatment with PE-exosomes (Figure 4, Paper III). Similarly, BAL exosomes from asthmatic 
patients can enhance CysLTs formation by bronchial epithelial cells [135]. PE-exosomes 
induced changes in the formation of other mediators, including PGD2, 20-HETE and TXB2. 
These results clearly shows that PE-exosomes can influence the release of tumor-promoting 
lipid mediators by cancer cells. The same vesicles also induced migration of both A549 cell 
and malignant cells from patient 12 (Figure 6, Paper III). The CysLT1 antagonist MK, a drug 
for asthma treatment, abolished this effect. MK is normally administrated as a 10 mg pill, 
which results in ~ 1 µM in blood after ~3 hours [248], the concentration which abrogated the 
exosome induced migration.  
Analysis of CysLT1 expression showed that PE-derived cancer cells from all 12 patients 
were positive for this receptor. In normal lungs CysLT1 is identified in smooth muscles and 
tissue macrophages, but not epithelium [24]. Inhibition of the LTD4/CysLT1 signaling 
pathway leads to cell death in malignant cells overexpressing CysLT1, indicating that 
CysLTs promote survival of cancer cells [249, 250]. In our study MK treatment induced 
apoptosis of the malignant lung cancer cells isolated from PEs in a dose-dependent manner, 
with IC50 ~6 µM (Figure 7, Paper III). Interestingly, PE-exosomes could partially counteract 
the cell death induced by MK, most likely by increasing the formation of CysLTs.  
In conclusion, exosomes and malignant cells present in PEs effectively form LTD4 and we 
speculate that LTD4 promotes the formation of novel metastatic niches. In fact, PE-cancer 
cells modulate the release of specific eicosanoids in response to exosomes, including CysLTs 
and the same PE-exosomes promote migration and survival of primary lung cancer cells via 
CysLT1. This is the first report to unveil the role of the exosomes/LTD4 machinery, in lung 
cancer, suggesting a novel way exosomes and LTs can contribute to tumor progression, in 
agreement with the ‘soil and seed’ theory.  
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Future plans:  
It is crucial to clarify which player of the TME contributes to the biosynthesis and 
metabolism of specific eicosanoids that may promote tumorigenesis [62]. Exosomes can 
promote tumorigenesis and the polarization of macrophages toward the M2 phenotype [136, 
251, 252]. Inspired by the effects on the PE-exosomes on PE-cancer cells, a next step can be 
to study the effect of PE-exosomes on macrophage polarization, with focus on the lipidomic 
profile, in order to understand how the phenotype of macrophages may affect the eicosanoid 
spectrum in the TME. Stimulation of macrophages with exosomes may also represent a 
model to mimic DAMP induced eicosanoid metabolism. 
Moreover, the results here reported promote the concept that targeting CysLTs may be a valid 
therapeutic approach in treatment of lung cancer. In fact, there is evidence in both animal 
models and humans that targeting CysLTs signaling pathways promote anti-tumor effects. 
Ablation of 5-LO in mice results in decreased influx of neutrophils to sustain metastasis 
formation in lungs, an effect driven by LTB4 and CysLTs [67]. MK treatment results in 
increased survival rate in mice with lung cancer [253] and a similar protective effect has been 
described for humans as well [68]. A 60 mg pill would produce a ~6 µM in plasma, the IC50 
required to induce apoptosis. This dosage does not give additional side effects, as 
demonstrated with patients taking 200 mg of MK for 5 months [254]. Moreover, we observed 
that MK could further enhance the cytotoxic effect of Doxorubicin and Cisplatin, common 
chemotherapeutic drugs. Thus, the mentioned studies and our results request further research 
to clarify the exact function of CysLT1 in lung cancer. Large cohorts of biological samples 
from patients with lung cancer may define the relationship between CysLT1 expression and 
prognosis, showed to be negative for patients with colon and breast cancer [255, 256]. Given 
that MK is an approved medication, we believe that there is potential for MK to be quickly 
included in clinical trials as therapy for patients with lung cancer.  
 
  
 38 
Conclusions 
This thesis brings together two different players of the inflammatory response, eicosanoids 
and exosomes. While we focused on macrophages and lungs from beginning, the initial goal 
of the first study was related to asthma. As it is well known, science is unpredictable, and we 
ended up with lung cancer. The connection of the main findings of this thesis is summarized 
in Figure 6.   
Figure 6. Three studies in one picture. 
 
In lungs, epithelial cells directly contribute to LTD4 biosynthesis: LTC4 is metabolized 
quickly via GGT-1 and slowly via GGT-5. Tumor exosomes also account for efficient 
formation of LTD4 via GGT-1. Myeloid cells are the principle source of LTC4, Macrophages 
display specific eicosanoid metabolism, depending on the differentiating factor and the 
trigger. M-CSF macrophages, primed toward the resolving endpoint, forms LTC4 effectively, 
due to efficient activation of LTs forming enzymes in response to PAMPs, and despite the 
lower expression of these enzymes. In the tumor microenvironment, macrophages donate 
LTC4 that malignant cells and exosomes convert to LTD4: LTD4/CysLT1 promotes migration 
and survival of cancer cells, possibly contributing to metastasis formation, suggesting a novel 
target for treatment of lung cancer. 
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